Tuesday, October 4, 2022


Biotechnology News Magazine

GenNext Technologies Announces $2.5M Grant Award

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, announced today the receipt of a two year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System.”

GenNext Technologies highlights the grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and Human Services. The purpose of the grant is to extend GenNext’s breakthrough Hydroxyl Radical Protein Footprinting (HRPF) technology and methods to studies involving living cells.

This award of $2.5 million brings total funding from NIGMS for the GenNext platform to $9.5 million.

The Flash Oxidation (Fox™) Protein Footprinting System is currently being used by the biopharmaceutical industry to perform Higher Order Structure (HOS) analysis of proteins with an emphasis on biologic therapeutics, the most rapidly growing segment in this area. The Fox System helps researchers develop safer and more effective biotherapeutics by revealing important information about protein interactions and structural changes.

With this award, we will complete our in-cell protein footprinting R&D program, culminating in a revolutionary new tool to study protein structure, protein interactions, and drug interactions in living cells. Soon, researchers will study living cells with a new level of simplicity and elegance, while generating unprecedented levels of actionable data,” said Scot R. Weinberger, Founder and CEO of GenNext. “We’re truly delighted to receive our tenth NIGMS grant award as further validation of our leadership in commercializing novel and robust protein footprinting technology.”


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine